# EDGAR Filing Document

**Accession Number:** 0001098972
**File Stem:** 0001193125-26-278647
**Filing Date:** 2026-6
**Character Count:** 7314
**Document Hash:** 8c57e7a7a5eee0ca53ca47509e23b779
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-278647.hdr.sgml**: 20260623

**ACCESSION NUMBER**: 0001193125-26-278647

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260616

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260623

**DATE AS OF CHANGE**: 20260623

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AGENUS INC
- **CENTRAL INDEX KEY:** 0001098972
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 061562417
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-29089
- **FILM NUMBER:** 261109423

**BUSINESS ADDRESS:**
- **STREET 1:** 3 FORBES ROAD
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
- **BUSINESS PHONE:** 781-674-4410

**MAIL ADDRESS:**
- **STREET 1:** 3 FORBES ROAD
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANTIGENICS INC /DE/
- **DATE OF NAME CHANGE:** 19991115

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 16, 2026<br>

------

AGENUS INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 000-29089 | 06-1562417 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 3 Forbes Road |  |  |
| Lexington**,** Massachusetts |  | 02421 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 781 674-4400<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | |
|:---|:---|
| **<br>Title of each class** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.01 par value per share<br> AGEN | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.07 Submission of Matters to a Vote of Security Holders.
Agenus Inc. (the "Company") held its Annual Meeting of Stockholders on June 16, 2026 (the "Annual Meeting"). A total of 27,098,077 shares of common stock, representing 65.24% of the shares outstanding and eligible to vote and constituting a quorum, were present at the Annual Meeting or represented by valid proxies. At the Annual Meeting, the Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 22nd, 2026: (i) to elect Garo Armen and Jennifer Buell as Class II Directors, each for a term of three years expiring at the 2029 Annual Meeting of Stockholders ("Proposal 1"); (ii) to approve an amendment to the Company's 2019 Employee Stock Purchase Plan (as amended) to increase the number of shares of common stock authorized for issuance thereunder from 150,000 shares to 200,000 shares ("Proposal 2"); (iii) to approve an amendment to the Company's Amended and Restated 2019 Equity Incentive Plan ("2019 EIP") to increase the aggregate shares available for issuance by 5,000,000 shares ("Proposal 3"); (iv) to approve a one-time stock option exchange program under the Company's 2019 EIP, the Amended and Restated 2009 Equity Incentive Plan, and the Company's 2015 Inducement Equity Plan, with premium strike prices applicable to director and executive officer replacement options ("Proposal 4"); (v) to approve, in a non-binding advisory vote, the compensation of the Company's named executive officers for 2025 ("Proposal 5") and (vi) to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 ("Proposal 6").

The Company's stockholders approved the Class II Director nominees recommended for election in Proposal 1 at the Annual Meeting.

The votes cast at the Annual Meeting were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Class II Director Nominee** | **For** | **Withheld** | **Broker Non-Votes** |
| Garo Armen | 13,371,144 | 6,116,636 | 7,610,297 |
| Jennifer Buell | 13,914,203 | 5,573,577 | 7,610,297 |

---

The Company's stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 15,162,365 | 4,154,008 | 171,407 | 7,610,297 |

---

The Company's stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 12,985,390 | 6,331,359 | 171,031 | 7,610,297 |

---

The Company's stockholders approved Proposal 4. The votes cast at the Annual Meeting were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 10,034,030 | 9,252,690 | 201,060 | 7,610,297 |

---

The Company's stockholders approved Proposal 5. The votes cast at the Annual Meeting were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 12,751,266 | 6,507,225 | 229,289 | 7,610,297 |

---

The Company's stockholders approved Proposal 6. The votes cast at the Annual Meeting were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 24,100,465 | 2,501,607 | 496,005 | 0 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | June 23, 2026 | By:  | /s/ Garo H. Armen |
|  |  |  | Garo H. Armen<br>Chairman and CEO |

---

------